Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Prevention of type 1 diabetes: today and tomorrow.

Cernea S, Dobreanu M, Raz I.

Diabetes Metab Res Rev. 2010 Nov;26(8):602-5. doi: 10.1002/dmrr.1138. Epub 2010 Oct 8.

PMID:
20936604
2.

[Survey of recent clinical trials of the prevention and immunointervention of type 1 diabetes mellitus].

Boerschmann H, Walter M, Achenbach P, Ziegler AG.

Dtsch Med Wochenschr. 2010 Feb;135(8):350-4. doi: 10.1055/s-0030-1249169. Epub 2010 Feb 17. Review. German.

PMID:
20166000
3.

Vaccine therapies for the prevention of type 1 diabetes mellitus.

Petrovsky N, Silva D, Schatz DA.

Paediatr Drugs. 2003;5(9):575-82. Review.

PMID:
12956615
4.

Prevention strategies for type 1 diabetes mellitus: current status and future directions.

Winter WE, Schatz D.

BioDrugs. 2003;17(1):39-64. Review.

PMID:
12534319
5.

Therapeutic targets for the prevention of type 1 diabetes mellitus.

Singh N, Palmer JP.

Curr Drug Targets Immune Endocr Metabol Disord. 2005 Jun;5(2):227-36. Review.

PMID:
16089357
6.

Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus.

Eldor R, Cohen IR, Raz I.

Int Rev Immunol. 2005 Sep-Dec;24(5-6):327-39. Review.

PMID:
16318985
7.

Prevention versus intervention of type 1 diabetes.

Brooks-Worrell B, Palmer JP.

Clin Immunol. 2013 Dec;149(3):332-8. doi: 10.1016/j.clim.2013.05.018. Epub 2013 Jun 10. Review.

PMID:
23803322
8.

Immunotherapy for the prevention and treatment of type 1 diabetes.

Goudy KS, Tisch R.

Int Rev Immunol. 2005 Sep-Dec;24(5-6):307-26. Review.

PMID:
16318984
9.

Mucosal insulin vaccination for type 1 diabetes prevention.

Bonifacio E, Achenbach P, Pan L, Ziegler AG.

Exp Clin Endocrinol Diabetes. 2008 Sep;116 Suppl 1:S26-9. doi: 10.1055/s-2008-1081484. Epub 2008 Sep 5. Review.

PMID:
18777449
10.

Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.

Achenbach P, Barker J, Bonifacio E; Pre-POINT Study Group..

Curr Diab Rep. 2008 Apr;8(2):87-93. Review.

PMID:
18445349
11.

Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes.

Pozzilli P, Guglielmi C, Maggi D, Carlone A, Buzzetti R, Manfrini S.

Curr Pharm Des. 2011;17(29):3224-8. Review.

PMID:
21864261
12.

Immunomodulation for the prevention of SPIDDM and LADA.

Pozzilli P, Guglielmi C.

Ann N Y Acad Sci. 2006 Oct;1079:90-8. Review.

PMID:
17130536
13.

Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.

Bisikirska BC, Herold KC.

Ann N Y Acad Sci. 2004 Dec;1037:1-9. Review.

PMID:
15699486
14.

Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes.

Azam A, Eisenbarth GS.

Expert Opin Biol Ther. 2004 Oct;4(10):1569-75. Review.

PMID:
15461568
15.

GAD65 autoimmunity-clinical studies.

Uibo R, Lernmark A.

Adv Immunol. 2008;100:39-78. doi: 10.1016/S0065-2776(08)00803-1. Review.

PMID:
19111163
16.

Trials in type 1 diabetes: Antigen-specific therapies.

Coppieters KT, Harrison LC, von Herrath MG.

Clin Immunol. 2013 Dec;149(3):345-55. doi: 10.1016/j.clim.2013.02.002. Epub 2013 Feb 15. Review.

PMID:
23490422
17.

New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.

Cernea S, Pozzilli P.

Diabet Med. 2008 Nov;25(11):1259-67. doi: 10.1111/j.1464-5491.2008.02556.x. Review.

18.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
19.

Anti-CD3 mAbs for treatment of type 1 diabetes.

Kaufman A, Herold KC.

Diabetes Metab Res Rev. 2009 May;25(4):302-6. doi: 10.1002/dmrr.933. Review.

PMID:
19319985
20.

Therapy with GAD in diabetes.

Ludvigsson J.

Diabetes Metab Res Rev. 2009 May;25(4):307-15. doi: 10.1002/dmrr.941. Review.

PMID:
19267332

Supplemental Content

Support Center